Fig. 1From: Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort studyStudy flowchart. P, pyrotinib; E, epirubicin; C, cyclophosphamide; T, paclitaxel/docetaxel; H, trastuzumab; tpCR, total pathologic complete response; bpCR, breast pathologic complete response; ORR, overall response rate; AEs, adverse eventsBack to article page